Cutting Edge: Myosin 18A Is a Novel Checkpoint Regulator in B Cell Differentiation and Antibody-Mediated Immunity.
Michael B CheungGospel Enyindah-AsonyeKen MatsuiIvan KosikNina DvorinaWilliam M BaldwinJonathan W YewdellNeetu GuptaPublished in: Journal of immunology (Baltimore, Md. : 1950) (2021)
We investigated the function of the newly discovered myosin family protein myosin 18A (Myo18A) in Ab-mediated immunity by generating B cell-conditional Myo18A-deficient mice. Myo18A deficiency led to expansion of bone marrow progenitor B cells and mature B cells in secondary lymphoid organs. Myo18A-deficient mice displayed serum IgM hyperglobulinemia and increased splenic IgM-secreting cells, with older mice switching to IgG1 hyperglobulinemia and autoantibody development. Immunization of Myo18A-deficient mice with inactivated influenza virus led to development of more potent neutralizing Abs against the major Ag hemagglutinin, associated with persistent accumulation of Ag-specific germinal center B cells and more Ag-specific bone marrow plasma cells. In vitro stimulation with TLR7 and BCR ligands revealed a greater ability of Myo18A-deficient B cells to differentiate into Ab-secreting cells, associated with higher AID and Blimp-1 expression. Overall, our study demonstrates that Myo18A is a novel negative regulator of B cell homeostasis, differentiation, and humoral immunity.
Keyphrases
- induced apoptosis
- bone marrow
- cell cycle arrest
- binding protein
- immune response
- mesenchymal stem cells
- quantum dots
- endoplasmic reticulum stress
- toll like receptor
- physical activity
- poor prognosis
- inflammatory response
- highly efficient
- cell proliferation
- transcription factor
- zika virus
- mass spectrometry
- pi k akt
- middle aged
- cell cycle
- single molecule
- anti inflammatory
- replacement therapy